Publications by authors named "Margit Schmeidl"
Article Synopsis
- - Frequent mutations in the KMT2C gene, particularly truncation mutations, are found in various cancers, including prostate cancer, but their biological effects have not been well understood.
- - Research involved knocking out the Kmt2c gene's catalytic core in mouse prostate tissue, revealing that impaired KMT2C activity promotes cancer cell proliferation, metastasis, and significantly reduces survival in cancer models.
- - The study links KMT2C mutations to poorer patient outcomes through increased MYC activity and decreased levels of the cell cycle repressor p16, suggesting that targeting MYC signaling could be a potential treatment strategy for affected prostate cancer patients.
Background: Targeted therapies offer novel opportunities to explore biomarkers based on their mode of action. Taking this into consideration, we evaluated six angiogenesis-related proteins as potential predictive biomarkers, which expression might predict the benefit of bevacizumab treatment in patients with metastatic colorectal cancer (mCRC).
Methods: This was a phase II multicenter, two-armed, randomized study, in which patients with mCRC were treated with XELIRI (capecitabine and irinotecan) plus bevacizumab followed by XELOX (capecitabine and oxaliplatin) plus bevacizumab (Arm A) or the reverse sequence (Arm B).
Stratification of patients with pancreatic ductal adenocarcinoma (PDAC) remains a key challenge in the field of clinical oncology. No predictive biomarkers have yet been found for any available treatment options. Previously, we identified SERPINB7 as a putative biomarker for PDAC and thus, herein, we aimed to validate our previous findings and assessed the predictive value of SERPINB7.
View Article and Find Full Text PDF